-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $13.25
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $13.25
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $13.25, but opened at $11.94. Janux Therapeutics shares last traded at $13.34, with a volume of 174 shares traded.
Janux Therapeutics Trading Up 2.3 %
The firm has a market capitalization of $564.91 million, a price-to-earnings ratio of -9.05 and a beta of 1.69. The stock has a fifty day moving average of $13.34 and a 200-day moving average of $13.04.
Get Janux Therapeutics alerts:Janux Therapeutics (NASDAQ:JANX – Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.04). The business had revenue of $2.37 million during the quarter. Janux Therapeutics had a negative return on equity of 15.10% and a negative net margin of 809.63%. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.74 earnings per share for the current fiscal year.
Institutional Trading of Janux Therapeutics
A number of institutional investors have recently bought and sold shares of JANX. Amalgamated Bank acquired a new stake in Janux Therapeutics during the first quarter valued at $28,000. Parkwood LLC boosted its position in Janux Therapeutics by 19.4% during the second quarter. Parkwood LLC now owns 33,750 shares of the company's stock valued at $34,000 after purchasing an additional 5,492 shares during the last quarter. American International Group Inc. lifted its position in shares of Janux Therapeutics by 25.3% in the first quarter. American International Group Inc. now owns 8,813 shares of the company's stock worth $126,000 after buying an additional 1,782 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Janux Therapeutics by 100.2% during the 1st quarter. MetLife Investment Management LLC now owns 10,614 shares of the company's stock worth $152,000 after acquiring an additional 5,312 shares in the last quarter. Finally, New York State Common Retirement Fund increased its holdings in shares of Janux Therapeutics by 63.0% during the 1st quarter. New York State Common Retirement Fund now owns 15,521 shares of the company's stock valued at $223,000 after acquiring an additional 6,000 shares during the last quarter. Institutional investors and hedge funds own 69.40% of the company's stock.Janux Therapeutics Company Profile
(Get Rating)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
See Also
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating) gapped down prior to trading on Tuesday . The stock had previously closed at $13.25, but opened at $11.94. Janux Therapeutics shares last traded at $13.34, with a volume of 174 shares traded.
JANUX治疗公司(纳斯达克：JANX-GET评级)周二盘前下跌。该股此前收盘报13.25美元，开盘报11.94美元。Janux Treateutics的股票尾盘报13.34美元，成交量为174股。
Janux Therapeutics Trading Up 2.3 %
Janux治疗公司股价上涨2.3%
The firm has a market capitalization of $564.91 million, a price-to-earnings ratio of -9.05 and a beta of 1.69. The stock has a fifty day moving average of $13.34 and a 200-day moving average of $13.04.
该公司的市值为5.6491亿美元，市盈率为-9.05倍，贝塔系数为1.69。该股的50日移动均线切入位为13.34美元，200日移动均线切入位为13.04美元。
Janux Therapeutics (NASDAQ:JANX – Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.04). The business had revenue of $2.37 million during the quarter. Janux Therapeutics had a negative return on equity of 15.10% and a negative net margin of 809.63%. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.74 earnings per share for the current fiscal year.
雅诺治疗公司(纳斯达克代码：JANX-GET评级)上一次发布财报是在8月9日星期二。该公司公布了该季度每股收益(0.41美元)，低于普遍预期的(0.37美元)和(0.04美元)。该业务本季度的收入为237万美元。雅诺治疗公司的净资产回报率为负15.10%，净利润率为负809.63%。股票研究分析师预测，Janux治疗公司本财年的每股收益将达到1.74美元。
Institutional Trading of Janux Therapeutics
JANUX治疗公司的机构交易
Janux Therapeutics Company Profile
Janux治疗公司简介
(Get Rating)
(获取评级)
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Janux治疗公司是一家生物制药公司，开发基于专有的肿瘤激活T细胞激活器(TRACTr)平台技术的疗法，用于治疗癌症患者。该公司处于临床前或发现阶段的主要候选TRACTr产品针对前列腺特异性膜抗原、表皮生长因子受体和滋养层细胞表面抗原2。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- 免费获取StockNews.com关于Janux治疗公司的研究报告(Janx)
- AMD股票是不是跌得太厉害了？
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它：投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗？
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得Janux治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Janux治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧